Results 151 to 160 of about 3,679,356 (272)

The efficacy of the combination of venetoclax and hypomethylating agents versus HAG agents in patients with acute myeloid leukemia: a retrospective study

Hematology
Objectives: The purpose of this study was to compare the effectiveness of the combination of venetoclax and hypomethylating agents with the HAG regimen.Methods: We studied 52 cases of newly diagnosed AML and 26 cases of relapsed refractory AML ...
Fei Xin, Yan-Hui Yu, Xu-Liang Shen, Guo-Xiang Zhang   +3 more
doaj   +1 more source

Serendipity: Decitabine monotherapy induced complete molecular response in a 77-year-old patient with acute promyelocytic leukemia [PDF]

, 2019
Abboud, Camille N, Abboud, Ramzi, Cashen, Amanda F, DiPersio, John F, Duncavage, Eric J, Han, Se Young, Shirai, Cara Lunn, Welch, John S   +7 more
core   +3 more sources

Safety and efficacy of azacitidine in myelodysplastic syndromes

Drug Design, Development and Therapy, 2010
Carlos E Vigil, Taida Martin-Santos, Guillermo Garcia-ManeroDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAPurpose: The clinical efficacy, different dosages, treatment schedules, and safety of azacitidine are ...
Carlos E Vigil, Taida Martin-Santos, Guillermo Garcia-Manero   +2 more
doaj  

TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes [PDF]

, 2016
et al,, Fronick, C. C., Fulton, R. S., Ley, T. J., Miller, C. A., O\u27Laughlin, M., Petti, A. A., Wartman, L. D., Wilson, R. K.   +8 more
core   +2 more sources

Loss of response to azacitidine is associated with deletion 12p13 in a patient with myelodysplastic syndrome with unique translocation t(13;17)(q12;q25) after prior breast cancer and acute promyelocytic leukemia [PDF]

, 2015
Jakšić, Ozren, Kušec, Rajko, Lasan-Trčić, Ružica, Lucijanić, Marko, Pejša, Vlatko, Štoos-Veić, Tajana   +5 more
core   +1 more source

Chromatin Perturbation Promotes Susceptibility to Hypomethylating Agents

Cancer-directed drugs are often clinically deployed without definitive understanding of their molecular mechanisms of action (MOA). Hypomethylating agents (HMAs), which result in the degradation of the DNA methyltransferase 1 (DNMT1), have been deployed for decades in the treatment of haematological malignancies1,2.
Constanze Schneider, Gabriela Alexe, Lucy A. Merickel, Ashleigh Meyer, Michelle L. Swift, Rodolfo B. Serafim, Allen T. Basanthakumar, Audrey Taillon, Silvi Salhotra, Fabio Boniolo, Sander Lambo, Yara Rodriguez, Björn Häupl, Rani E. George, David E. Root, Thomas Oellerich, Volker Hovestadt, Dipanjan Chowdhury, Kimberly Stegmaier   +18 more
openaire   +2 more sources

Development of the treatment preference in myelodysplasia questionnaire for clinicians, carers, and patients

eJHaem
This study reports the development activities for the Treatment Preference Myelodysplasia Questionnaires (TPMQ) for clinicians (mTPMQ), carers (cTPMQ), and patients (pTPMQ).
Robert Morlock, Chun Fong, Francesco Castaldi, Taliesha Paine, Donna Collett, Anoop Enjeti   +5 more
doaj   +1 more source

Acute Myeloid Leukemia in the Elderly Patient: New Strategies [PDF]

, 2015

core   +1 more source

The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation [PDF]

, 2017

core   +1 more source

Hypomethylating agents in vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome (VEXAS): A systematic review. [PDF]

Br J Haematol
Hoff FW, Trikha R, Groarke EM, Patel BA.
europepmc   +1 more source